This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Sep 27;384(9949):1164-6.

doi: 10.1016/S0140-6736(14)60962-4. Epub 2014 Jun 11.

Initiating dopaminergic treatment in Parkinson's disease

Anthony E Lang¹, Connie Marras²

Affiliations

Affiliations

¹ The Edmond J Safra Program in Parkinson's Disease, University Health Network, Toronto, ON, Canada; Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 2J7, Canada. Electronic address: lang@uhnres.utoronto.ca.
² The Edmond J Safra Program in Parkinson's Disease, University Health Network, Toronto, ON, Canada; Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 2J7, Canada.

PMID: 24928806
DOI: 10.1016/S0140-6736(14)60962-4

Comment

Initiating dopaminergic treatment in Parkinson's disease

Anthony E Lang et al. Lancet. 2014.

. 2014 Sep 27;384(9949):1164-6.

doi: 10.1016/S0140-6736(14)60962-4. Epub 2014 Jun 11.

Authors

Anthony E Lang¹, Connie Marras²

Affiliations

¹ The Edmond J Safra Program in Parkinson's Disease, University Health Network, Toronto, ON, Canada; Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 2J7, Canada. Electronic address: lang@uhnres.utoronto.ca.
² The Edmond J Safra Program in Parkinson's Disease, University Health Network, Toronto, ON, Canada; Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 2J7, Canada.

PMID: 24928806
DOI: 10.1016/S0140-6736(14)60962-4

No abstract available

PubMed Disclaimer

Comment on

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.

Similar articles

What is the best initial treatment in Parkinson's disease?
Sharp ME, Mazzoni P. Sharp ME, et al. J R Coll Physicians Edinb. 2014;44(4):291-2. doi: 10.4997/JRCPE.2014.409. J R Coll Physicians Edinb. 2014. PMID: 25516899 No abstract available.
Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease.
Hauser RA. Hauser RA. Evid Based Med. 2015 Feb;20(1):17. doi: 10.1136/ebmed-2014-110115. Epub 2014 Dec 18. Evid Based Med. 2015. PMID: 25525039 No abstract available.
Guideline for the treatment of Parkinson's disease.
Carr J, Kies B, Fine J; Movement Disorders Group of South Africa. Carr J, et al. S Afr Med J. 2009 Oct;99(10):755-6, 758. S Afr Med J. 2009. PMID: 20128276 No abstract available.
Pharmacological treatment of Parkinson's disease.
Münchau A, Bhatia KP. Münchau A, et al. Postgrad Med J. 2000 Oct;76(900):602-10. doi: 10.1136/pmj.76.900.602. Postgrad Med J. 2000. PMID: 11009573 Free PMC article. Review. No abstract available.
Treatment Strategies in Early Parkinson's Disease.
Marsili L, Marconi R, Colosimo C. Marsili L, et al. Int Rev Neurobiol. 2017;132:345-360. doi: 10.1016/bs.irn.2017.01.002. Epub 2017 Feb 16. Int Rev Neurobiol. 2017. PMID: 28554414 Review.

See all similar articles

Cited by

Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors.
Rehuman NA, Oh JM, Abdelgawad MA, Beshr EAM, Abourehab MAS, Gambacorta N, Nicolotti O, Jat RK, Kim H, Mathew B. Rehuman NA, et al. Pharmaceuticals (Basel). 2022 Sep 16;15(9):1152. doi: 10.3390/ph15091152. Pharmaceuticals (Basel). 2022. PMID: 36145373 Free PMC article.
Estimates of Intracellular Dopamine in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Sackner-Bernstein J. Sackner-Bernstein J. J Parkinsons Dis. 2021;11(3):1011-1018. doi: 10.3233/JPD-212715. J Parkinsons Dis. 2021. PMID: 34024786 Free PMC article.
Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.
Lopane G, Mellone S, Corzani M, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M. Lopane G, et al. J Neurol. 2018 Jun;265(6):1343-1352. doi: 10.1007/s00415-018-8848-1. Epub 2018 Mar 29. J Neurol. 2018. PMID: 29600390 Clinical Trial.
Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.
Wang L, Xiong N, Huang J, Guo S, Liu L, Han C, Zhang G, Jiang H, Ma K, Xia Y, Xu X, Li J, Liu JY, Wang T. Wang L, et al. Front Aging Neurosci. 2017 Jun 28;9:206. doi: 10.3389/fnagi.2017.00206. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28701947 Free PMC article. Review.
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Zhang J, Tan LC. Zhang J, et al. Curr Neuropharmacol. 2016;14(4):356-63. doi: 10.2174/1570159x14666151208114634. Curr Neuropharmacol. 2016. PMID: 26644151 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information